INBUILD-ON (NCT03820726) was an open-label extension trial investigating long-term safety and efficacy of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. It was a pleasure to talk with Dr. Eric Matteson (Mayo Clinic College of Medicine and Science, Rochester, MN, USA) to discuss the aims, eligibility criteria and the most common adverse events reported in INBUILD-ON.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON.’ (Abstract number: 0186) was presented at the ACR Convergence, November 10–14, 2022.
- What did the INBUILD study teach us about the efficacy and safety of nintedanib on patients with progressive fibrosing ILDs?
- What are the aims and eligibility criteria of the INBUILD-ON study?
- What were the most common adverse events of nintedanib reported in INBUILD-ON?
- What were the conclusions regarding future use of nintedanib in this patient population?
Disclosures: Eric Matteson discloses consulting for Boehringer Ingelheim and Alvotech Inc; receiving honoraria from Practice Point Communications and Boehringer Ingelheim; participating on speaker’s bureaus for Practice Point Communications; and other financial support from UpToDate and Horizon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatic Diseases
NRAS’s mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society
We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS’s profound impact on the RA community, and her role and experiences within the NRAS, and pivotal contributions to pioneering […]
A patient’s perspective – journey to diagnosis of seronegative rheumatoid arthritis: Ailsa Bosworth, National Rheumatoid Arthritis Society
We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the […]
Juvenile Idiopathic Arthritis Awareness Week 2023 – Clare Jacklin, NRAS
Juvenile idiopathic arthritis awareness week (JIAAW) is taking place between 3-7 July to raise awareness and dispel misconceptions around JIA, this year’s theme is #BustingJIAMyths, you can take part by entering the ‘JIA Mythbuster’ quiz and joining the conversation on social media using #BustingJIAMyths and #JIAAW2023. touchIMMUNOLOGY were delighted to talk with CEO Clare Jacklin and support […]